Transforming Care. Empowering Lives.

At Belenos Biosciences Inc., we believe that clinical remission should be the standard—not the exception—for treating chronic inflammatory diseases like COPD, asthma and atopic dermatitis. Our bispecific therapeutics are designed to target proven disease pathways, with the goal of delivering meaningful, lasting outcomes for patients. With a focus on innovation and speed, we are advancing our pipeline with urgency to bring next-generation treatments to those who need them most.

The Belenos Team

Proven Expertise. Relentless Drive.

Belenos Biosciences was founded by a veteran team with deep expertise in chronic inflammatory diseases and a track record of success across every stage of drug development—from discovery to commercial launch. Agile and execution-focused, our leadership thrives on solving complex challenges with speed and precision.

What unites us is a single mission: to push beyond today’s efficacy limits and deliver best-in-class therapies to patients—faster.

Belenos Biosciences: Donnie McGrath

Donnie McGrath, M.D., M.P.H.

Donnie McGrath is a Venture Partner at OrbiMed Advisers LLC. Prior to founding Belenos Biosciences, he was Founder and Executive Chairman of BioShin (Shanghai), and Chief of Corporate Strategy and Business Development at Biohaven Pharmaceuticals, until their acquisition by Pfizer in 2022. Previously, he was Vice President, Business Development and Head of Search of Evaluation for Bristol-Myers Squibb. Donnie began his career treating patients as an infectious disease physician in the Division of Geographic Medicine and Infectious Disease at Tufts New England Medical Center. Donnie earned his medical degree from the Royal College of Surgeons in Ireland, and his M.P.H. from the Harvard School of Public Health.

Belenos Biosciences: Megan Dow

Megan Dow, Ph.D.

Megan Dow has extensive leadership experience growing biotechs and pipelines. Prior to co-founding Belenos, Megan was Vice President and Head of Portfolio & Corporate Strategy at Biohaven, covering numerous therapeutic areas from discovery to Phase 3. Before Biohaven, she worked in the Chief Business Office at Pfizer on R&D Strategy across the portfolio. Previously, Megan was the Senior Life Science Advisor for Denmark based in NYC, where she led the U.S. investment, partnering, and portfolio development strategies for Danish biotech and pharma companies. Megan began her career as an equity research analyst covering biotech, and remains on the Steering Committee for the New York Academy of Sciences. She is an immunologist by training, and earned her Ph.D. in Pathobiology and Immunology at NYU School of Medicine.
Belenos Biosciences: Tania Dimitrova

Tania Dimitrova, M.B.A

Tania Dimitrova has 20 years of experience in bio-pharma business and corporate development, capital markets and investing. Prior to co-founding Belenos, she was Chief Business Officer at Artios, where she led strategic transactions, including business collaborations with Merck KGaA and Novartis, positioning the company for a successful Series C financing. Earlier, Tania held various roles in Worldwide Business Development at Pfizer and Corporate M&A at Bristol-Myers Squibb, where she executed over 25 transactions with immediate value of over $20 billion and received two Transactionalist Excellence Awards. Tania spent the first half of her career in healthcare investment banking as an equity research associate and a senior healthcare buy-side analyst in asset management. She earned her MBA from the Wharton School at the University of Pennsylvania and holds a BA in Economics and Mathematics from Mount Holyoke College.
Belenos Biosciences: Glenn Rosen

Glenn Rosen, M.D.

Glenn D. Rosen is an emeritus Associate Professor of Medicine in Pulmonary and Critical Care Medicine at Stanford University. At Stanford, Glenn served as Division Co-Chief of Pulmonary and Critical Care Medicine led the Interstitial Lung Disease Program at the Advanced Lung Disease Center. In addition to his time at Standford, Glenn was Head of Discovery Fibrosis Biology at Bristol-Myers Squibb, where he led early discovery and development efforts, focusing on liver and lung fibrosis, resulting in the clinical development for drugs to treat IPF and lung disease.

Belenos Biosciences: Nick Vrolijk

Nick Vrolijk, Ph.D.

Nick has 29 years’ of biopharmaceutical professional experience leading CMC operations with small and mid-sized biopharmaceutical companies. He has successfully participated in and/or led the submission of multiple INDs and several BLAs/NDAs. Nick received his Ph.D in marine biochemistry from the University of Delaware and was an NSF post-doctoral fellow at the University of Maryland.
Belenos Biosciences: Anna Rightmire

Anna Rightmire

Anna Rightmire has nearly 30 years of experience in clinical operations in the pharmaceutical and biotech industry. Anna was a key member of the infectious disease clinical operations team at Bristol-Myers Squibb before moving to ViiV as Director of Clinical Operations leading HIV drug development operations. Prior to joining Belenos, Anna was a Senior Director of Clinical Operations at Biohaven.

Daniel Franjic, M.D, Ph.D.

Vice President, Clinical Development

Jennifer Madonia, P.A.

Sr. Medical Director, Clinical Development

Michelle DeGrosky

Sr. Director, ​Clinical Operations

Sam Amoresano

Comptroller

Mark Carlson, Ph.D.​

Ex. Director, Program Management 

Sarah Lipson

Sr. Manager, Business Operations

Avery Tyler

Business Operations Associate

 

Samantha Wong

Strategic Operations Associate

Belenos Biosciences

Our Pipeline

Dual-Targeted Innovation. Long-Acting Impact.

IND Enabling
Early Clinical
Late Clinical
Registration
BEL512
TSLP/IL-13
Asthma
Atopic Dermatitis
COPD
CRSwNP
CSU
2027
Phase 3
Studies
BEL536
OX40L/IL-13
Atopic Dermatitis
Food Allergy
Scleroderma
2027/2028
Phase 3
Studies

Belenos is advancing a differentiated pipeline of long-acting bispecific antibodies designed to transform the treatment of chronic inflammatory diseases.

Our lead candidate, BEL512, targets TSLP and IL-13, two central cytokines that act at distinct but complementary levels of type 2 inflammation. TSLP is an upstream epithelial alarmin that initiates and amplifies immune cascade activation, while IL-13 is a key downstream effector driving tissue inflammation, barrier dysfunction, and remodeling. Preclinical and emerging clinical evidence support that simultaneous modulation of upstream epithelial signaling and downstream effector pathways may enable more comprehensive control of chronic type 2 inflammatory responses than inhibition of either pathway alone.

BEL512 is designed to both suppress upstream triggers and downstream cytokine effector blockade together within a single long-acting bispecific molecule. By addressing both initiation and maintenance mechanisms of type 2 inflammation, BEL512 is intended to provide durable control of heterogenous disease biology rather than isolated pathway inhibition. BEL512 entered clinical development in 2024 and is being advanced for multiple diseases characterized by epithelial-immune dysregulation, including asthma, CRSwNP, COPD, CSU, and atopic dermatitis.

Our second candidate, BEL536, is a first-in-class bispecific antibody that targets OX40L and IL-13, two complementary drivers of inflammatory disease biology spanning immune activation and tissue effector pathways. OX40L is a critical costimulatory ligand that sustains pathogenic T-cell activation, expansion, and persistence across multiple helper T-cell lineages, including type 1, type 2, and type 3 inflammatory responses, while IL-13 is a central effector cytokine responsible for tissue inflammation, barrier dysfunction, and remodeling in type 2 disease. Our preclinical studies indicate that concurrent modulation of OX40L-dependent T-cell amplification and IL-13–mediated effector pathways enable broader and more durable suppression of inflammatory responses than inhibition of either pathway alone.

BEL536 is designed to integrate immune circuit modulation with downstream cytokine effector blockade in a single long-acting bispecific antibody. By attenuating OX40L-driven T-cell costimulation, thereby impacting Th1, Th2, and Th17 pathways, while concurrently suppressing IL-13–driven tissue pathology, BEL536 is intended to address both immune activation and tissue-level disease mechanisms. BEL536 entered the clinic in 2026 and is being developed for chronic inflammatory diseases characterized by sustained T-cell activation with overlapping type 1, type 2, and type 3 inflammatory features, including atopic dermatitis, food allergy, and related immune-mediated disorders.

Both of BEL512 and BEL536 seek to break the efficacy barrier and provide patient friendly dosing.